Stockreport

Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of Medicine

Akero Therapeutics, Inc.  (AKRO) 
Last akero therapeutics, inc. earnings: 3/16 07:30 am Check Earnings Report
PDF Results support potential benefit of efruxifermin (EFX) to elicit fibrosis improvement in patients with compensated cirrhosis (F4 fibrosis) due to MASH 96-week data from [Read more]